Meta-analysis compares infection rates of teclistamab in clinical trials and real-world evidence
Teclistamab linked to higher infection rates in some patients
This meta-analysis of 714 patients evaluates the incidence of infections in relapsed/refractory multiple myeloma treated with teclistamab.
New data shows that patients using teclistamab for multiple myeloma may face a significant risk of developing various types of infections.
Case report highlights diagnostic challenges between POEMS syndrome and CIDP
Misdiagnosis of rare nerve disorder highlights need for vigilance
This case report and literature review describes a single patient with POEMS syndrome who was initially misdiagnosed with CIDP.
A single patient's journey from a wrong diagnosis to the truth reveals how easily rare nerve conditions can be missed.
Meta-analysis of CD38-directed CAR-T therapy in relapsed refractory multiple myeloma reports high response rates
New CD38 CAR-T therapy shows high success rates for late-stage multiple myeloma patients
This systematic review and meta-analysis evaluated CD38-directed CAR-T cell therapy in patients with relapsed refractory multiple myeloma.
A new immune therapy targeting CD38 and BCMA offers deep remission for late-stage multiple myeloma patients while managing side effects like…
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma.
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Systematic review of MS proteomics/metabolomics in multiple myeloma cohorts
New Blood Test Spots Myeloma Return Months Earlier
This systematic review synthesizes evidence from 19 studies involving 1,077 screened records regarding quantitative mass spectrometry-based …
This new test could give patients and doctors a critical head start in fighting a return of multiple myeloma.
Case Report Describes Non-Secretory Multiple Myeloma With Eosinophilia in a 56-Year-Old Man
Back Pain and High White Cells: A Hidden Cancer Case
This case report details a 56-year-old man presenting with multiple myeloma and eosinophilia.
This case shows how a rare blood cancer can hide behind common symptoms, making early diagnosis difficult but crucial.
Belantamab mafodotin plus lenalidomide and dexamethasone shows high response in unfit multiple myeloma
Early trial shows promising results for a new drug combination in frail multiple myeloma patients
A Phase 1/2 randomized controlled trial in 42 RP2D patients with unfit, transplant-ineligible newly diagnosed multiple myeloma found an over…
A new drug combination helped 97.6% of frail multiple myeloma patients respond to treatment while keeping eye side effects manageable.
Talquetamab and teclistamab combination shows 79% response in relapsed multiple myeloma with extramedullary disease
Study looks at two antibody drugs for high-risk multiple myeloma
This phase 2 single-arm study evaluated a talquetamab and teclistamab combination in a high-risk population with relapsed/refractory multipl…
A new drug combo for high-risk multiple myeloma helped 79% of patients respond, but 31% faced serious infections and five treatment-related …
Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease
Bone Pain in Cancer: New Options, Real Risks
This review article examines the use of bisphosphonates and denosumab in patients with multiple myeloma.
New drugs target bone breakdown in multiple myeloma without kidney damage, offering hope for patients with weak bones and severe pain.
BR regimen shows survival outcomes in newly diagnosed Waldenstroms Macroglobulinemia patients
A Rare Blood Cancer With an 8-Year Survival: What Real-World Data Shows
This single-center retrospective analysis evaluated 89 newly diagnosed Waldenstroms Macroglobulinemia patients treated with the BR regimen.
New real-world data shows patients with the rare blood cancer Waldenstrom's macroglobulinemia live a median of over 8 years after diagnosis.